If you are referring to Gileads long acting prep trial, while their study population has a lot of overlap the Cytodyn HIV study is looking at a completely different impact on inflammation with a CRP primary endpoint, Gilead is looking functionally at an ART impact. Jonah Sacha’s efforts on long acting Leronlimab would potentially be a leapfrog over Gilead by covering both immune modulation as well as halting viral replication but we’re getting ahead of ourselves. That said, I think the fireworks are going to come with MSS CRC, there is a reason that is priority one.